News

According to a recent C.S. Mott Children’s Hospital National Poll on Children’s Health, the recent wildfires and extreme weather events that are creating poor or unhealthy air quality are also causing concern for parents in regards to their children's health.

Standout updates include a relaxed recommendation for patients with a history of egg allergies, and that all available influenza vaccines for the 2023 to 2024 flu season are quadrivalent.

This new data expands upon limited current research on environmental elements that contribute to the extensive variation in symptoms and infection frequency seen in children.

How pediatricians can best manage electronic health records without compromising patient care.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.

Two infant formula products are being voluntarily recalled by the LittleOak Company after the FDA deemed they were illegally sold in the United States.

Hair loss is a condition that is often distressing and difficult to treat, particularly in adolescents. Here’s what you should know.

Surveys collected for a study published in the Canadian Journal of Diabetes revealed that desire for telehealth care amid pediatric diabetes families increased from the early onset of the COVID-19 pandemic, to more than 1 year later.

A look at the advantages and limitations of these platforms.

The 2023 guideline for managing diabetes in children and adolescents highlights risk factors and treatment for type 1 and type 2 diabetes.

In a recent study, strategies and goals for adolescent engagement with patient portals differed across US hospitals.

A supplemental biologics license application for ALTUVIIIO (Antihemophilic factor; Sanofi) has been accepted by the FDA for use in patients aged 12 years and younger with severe hemophilia A.

In a recent study, the prediction accuracy of an AlignProCARE model for adolescent idiopathic scoliosis was often better than that of clinicians.

Bivalent COVID-19 vaccines by both Moderna and Pfizer-BioNTech are no longer authorized for use in the United States.

In a recent study, pediatric patients residing in low-opportunity neighborhoods were less likely to be up to date on preventive care visits.

A refresher on best interventions for common respiratory disorders in children.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Attacks are having an effect on care delivery, according to a cybersecurity study.

Numerous tools, technology platforms, and interventions have been developed to help teens with the difficult emotional and physical weight of managing the disease.

In this Contemporary Pediatrics interview, Rob Knight, PhD, discusses translating adult studies into children to determine gut microbiome biomarkers, and how they are associated with neurological and cognitive conditions.

The technology may be new, but the position we find ourselves in as clinicians is not.

A dream come true for Judah, and the 12,000th wish for Make-A-Wish New Jersey.

Due to increased RSV activity observed in Southeastern regions of the United States, the Centers for Disease Control and Prevention (CDC) has issued an official Health Alert Network Health Advisory. The CDC recommends that clinicians prepare to implement recently FDA-approved prevention methods.

The EarliPoint Evaluation has demonstrated positive phase 3 trial results, aiding in autism diagnosis and assessment in children aged 16 to 30 months. Warren Jones, PhD, chief scientific officer and cofounder of EarliTec Diagnostics, Inc., discusses the eye-tracking tool, how it is currently being used, and what could be in store for the future.

In this Contemporary Pediatrics interview, Bernard A. Cohen, MD, discusses VP-102, approved by the FDA on July 22, 2023, to treat molluscum contagiosum in pediatric patients 2 years and up.

The effects of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in patients aged 9 to 15 years has indicated efficacy, according to a recent long-term follow-up study.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.